Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. High prevalence of hepatitis is expected to propel growth of the hepatitis drugs market. In May 2019, according to the study, ‘Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda’, published in May 2019, in BMC Infectious Diseases, the prevalence of hepatitis B surface antigen was 3.9% in the study population. Moreover, increasing vigilance around liver health is also expected to aid in growth of the hepatitis drugs market. Echosens, a provider of non-invasive diagnostic products and services for liver diagnosis, urged increased vigilance around liver health during May 2020 Hepatitis Awareness Month.
Players in the hepatitis drugs market are focused on adopting M&A activities. In December 2020, Gilead Sciences signed a definitive agreement to acquire German biotechnology company MYR for approximately US$ 1.4 billion in cash. With this deal, Gilead will acquire First-in-Class entry inhibitor Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV), a severe form of viral hepatitis. Players in the hepatitis drugs market are also focused on adopting collaboration strategies. In January 2021, Gilead Sciences, Inc. collaborated with Vir Biotechnology, Inc. to evaluate therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus.
Recently, in June 2021, Gilead Sciences Inc. received the US Food and Drug Administration approval for an expansion of the pediatric indication of Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C virus to now include children as young as 3 years of age, regardless of HCV genotype or liver disease severity. Such approval are expected to aid in growth of the hepatitis drugs market.
According to the 2018 Humboldt County Community Health Assessment, in 2016, there were more than 500 new cases of HCV diagnosed, and seven ZIP codes reached rates of 20% or higher. Moreover, according to data from the California Department of Public Health, Humboldt County experienced a 26% increase in HCV cases between 2014 and 2018. Such increasing cases aid in growth of the hepatitis drugs market in North America. Approval and launch of new drugs is expected to propel growth of hepatitis drugs market in Europe. In June 2021, Grifols launched HyperHEP B, a new formulation of its hepatitis B immune globulin [human] for hepatitis B postexposure prophylaxis.
No comments:
Post a Comment